MiR-410-3p Facilitates Angiotensin II-induced Cardiac Hypertrophy by Targeting Smad7
Overview
Affiliations
MicroRNAs (miRNAs) have emerged as important regulators in the development of cardiovascular diseases. miR-410-3p was shown to play a protective or detrimental role in the progression in cardiovascular events. However, the exact role and the underlying mechanism of miR-410-3p in cardiac hypertrophy have not been documented. The current work was aimed to determine the role and underlying mechanism of miR-410-3p on Angiotensin II (Ang II) induced cardiac hypertrophy. FITC-phalloidin staining was used for determination of cardiomyocyte surface area. Quantitative reverse transcription polymerase chain reaction (qRT-PCR) was performed to identify mRNA expression level of hypertrophic markers. Smad7 protein expression level was analyzed using Western blot. Dual-luciferase reporter assay was used to examine the regulatory function of miR-410-3p on Smad7. MiR-410-3p was found significantly up-regulated in Ang II-induced cardiac hypertrophy. MiR-410-3p inhibitor remarkably alleviated cardiomyocyte hypertrophic changes. Dual-luciferase reporter assay result indicated that miR-410-3p directly targeted Smad7 and miR-410-3p inhibitor effectively prevented Ang II triggered down-regulation of Smad7. Moreover, Smad7 overexpression significantly reversed the pro-hypertrophic effect of miR-410-3p. In summary, our findings revealed that miR-410-3p mediated Ang II-induced cardiac hypertrophy via targeting inhibition of Smad7.
Microrna363-5p targets thrombospondin3 to regulate pathological cardiac remodeling.
Ma Y, Han X, Zan S, Liu H, Zhou X, Zhao D Mol Cell Biochem. 2024; .
PMID: 39373825 DOI: 10.1007/s11010-024-05125-7.
Cardiovascular Disease and miRNAs: Possible Oxidative Stress-Regulating Roles of miRNAs.
Lee S Antioxidants (Basel). 2024; 13(6).
PMID: 38929095 PMC: 11200533. DOI: 10.3390/antiox13060656.
Noncoding RNAs as Key Regulators for Cardiac Development and Cardiovascular Diseases.
Kawaguchi S, Moukette B, Hayasaka T, Haskell A, Mah J, Sepulveda M J Cardiovasc Dev Dis. 2023; 10(4).
PMID: 37103045 PMC: 10143661. DOI: 10.3390/jcdd10040166.
4'‑O‑methylbavachalcone inhibits succinate induced cardiomyocyte hypertrophy via the NFATc4 pathway.
Sun H, Zhu G, Ling S, Liu J, Xu J Exp Ther Med. 2023; 25(4):172.
PMID: 37006873 PMC: 10061262. DOI: 10.3892/etm.2023.11871.
Wang Z, Tian Q, Tian Y, Zheng Z Bioengineered. 2022; 13(5):13328-13340.
PMID: 35635065 PMC: 9275898. DOI: 10.1080/21655979.2022.2081757.